Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 85,920,808
  • Shares Outstanding, K 2,531,550
  • Annual Sales, $ 23,002 M
  • Annual Income, $ 3,499 M
  • 36-Month Beta 0.77
  • Price/Sales 3.72
  • Price/Cash Flow 10.94
  • Price/Book 5.79

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.26 +5.21%
on 07/13/17
34.90 -2.75%
on 06/27/17
-1.21 (-3.44%)
since 06/26/17
3-Month
30.20 +12.38%
on 04/28/17
35.60 -4.66%
on 06/22/17
+3.36 (+10.99%)
since 04/26/17
52-Week
25.55 +32.84%
on 12/07/16
35.60 -4.66%
on 06/22/17
+3.03 (+9.80%)
since 07/26/16

Most Recent Stories

More News
Ironwood (IRWD) Reports Positive Data on Reflux Candidate

Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.

ENZ : 11.29 (+1.07%)
IRWD : 17.10 (+0.35%)
AZN : 33.94 (+0.47%)
IONS : 54.33 (-0.69%)
Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

AZN : 33.94 (+0.47%)
JNJ : 130.95 (-0.71%)
MRK : 61.80 (-0.90%)
LLY : 81.84 (-0.43%)
NVS : 84.85 (+0.77%)
SNY : 48.02 (-0.10%)
BMY : 55.98 (+0.05%)
AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

AZN : 33.94 (+0.47%)
TEVA : 33.04 (+0.85%)
RHHBY : 31.6600 (-0.44%)
SNY : 48.02 (-0.10%)
Arena Announces Secondary Stock Worth $150M (revised)

Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.

ENZ : 11.29 (+1.07%)
AZN : 33.94 (+0.47%)
ARNA : 24.37 (+0.08%)
EXEL : 28.02 (+2.23%)
Pfizer Xeljanz Label Expansion Application Accepted by FDA

Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.

AZN : 33.94 (+0.47%)
MRK : 61.80 (-0.90%)
PFE : 32.89 (-0.63%)
SNY : 48.02 (-0.10%)
J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab

Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed...

AZN : 33.94 (+0.47%)
JNJ : 130.95 (-0.71%)
NVS : 84.85 (+0.77%)
ABBV : 72.59 (+0.10%)
Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.

Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.

MYL : 39.19 (+0.95%)
AZN : 33.94 (+0.47%)
JNJ : 130.95 (-0.71%)
LLY : 81.84 (-0.43%)
NVS : 84.85 (+0.77%)
PFE : 32.89 (-0.63%)
SNY : 48.02 (-0.10%)
Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion

We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.

AZN : 33.94 (+0.47%)
CLVS : 87.43 (+1.70%)
TSRO : 130.06 (+0.86%)
PFE : 32.89 (-0.63%)
Lilly Settles Patent Litigation on Cialis with Generic Firms

Eli Lilly & Company (LLY) announced that it has entered into an agreement with generic companies to settle a patent relating to its erectile dysfunction drug Cialis (tadalafil).

AZN : 33.94 (+0.47%)
MRK : 61.80 (-0.90%)
LLY : 81.84 (-0.43%)
SNY : 48.02 (-0.10%)
Mallinckrodt to Pay $35M for Controlled Substances Probe

Mallinckrodt plc (MNK) recently finalized the agreement which it had reached with the U.S. Drug Enforcement Administration (DEA) and the U.S. Attorneys' Offices (USAOs) for the Eastern District of Michigan...

ENZ : 11.29 (+1.07%)
AZN : 33.94 (+0.47%)
ENDP : 11.31 (-2.08%)
MNK : 46.43 (-2.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Support & Resistance

2nd Resistance Point 34.17
1st Resistance Point 34.05
Last Price 33.94
1st Support Level 33.77
2nd Support Level 33.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.